Phase II Trial Of Neoadjuvant Bevacizumab With Modified FOLFOX7 In Patients With Stage II And III Rectal Cancer

Trial Profile

Phase II Trial Of Neoadjuvant Bevacizumab With Modified FOLFOX7 In Patients With Stage II And III Rectal Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 30 May 2018

At a glance

  • Drugs Bevacizumab (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Rectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 May 2018 Planned End Date changed from 2 Aug 2019 to 2 Aug 2020.
    • 23 May 2018 Planned primary completion date changed from 2 Aug 2018 to 2 Aug 2019.
    • 23 May 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top